SCHEMBL25285372

SCHEMBL25285372

COc1ccc(C2=NOC3CS(O)(O)CC23)cc1C(=O)O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 1/20 0.37
HSP90AB1 P08238 1/20 0.37
MIF P14174 3/20 0.37
SYK P43405 1/20 0.37
CFD P00746 1/20 0.36
ALDH1A1 P00352 4/20 0.36
KDM4E B2RXH2 3/20 0.36
MAPK1 P28482 3/20 0.36
HSD17B10 Q99714 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
APAF1 O14727 1/20 0.36
RECQL P46063 1/20 0.36
CASP6 P55212 1/20 0.36
CACNA1B Q00975 1/20 0.36
APBA1 Q02410 1/20 0.36
MCL1 Q07820 1/20 0.36
CASP8 Q14790 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
GAA P10253 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25285387 0.90 MAPK1 (0.38) HSP90AA1HSP90AB1MIFALDH1A1KDM4E
SCHEMBL25279143 0.89 MIF (0.37) HSP90AA1HSP90AB1MIFSYKCFD
SCHEMBL30361951 0.89 MIF (0.37) HSP90AA1HSP90AB1MIFSYKCFD
SCHEMBL25281532 0.82 MTOR (0.40) MIFSYKCFDALDH1A1KDM4E
SCHEMBL26103646 0.82 AR (0.47) KDM4EAPAF1RECQLCASP6CACNA1B
SCHEMBL30457516 0.81 MIF (0.37) MIFSYKCFDALDH1A1KDM4E
SCHEMBL30362037 0.81 MIF (0.37) MIFSYKCFDALDH1A1KDM4E
SCHEMBL26107590 0.81 MIF (0.37) MIFSYKCFDALDH1A1KDM4E
SCHEMBL25271699 0.81 MIF (0.37) MIFSYKCFDALDH1A1KDM4E
SCHEMBL25239901 0.79 MIF (0.38) HSP90AA1HSP90AB1MIFALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250221966-A1 RXFP1 AGONISTS BRISTOL MYERS SQUIBB CO (US) 2025-07-10 US disclosed
US-20250066344-A1 BENZOTHIAZOLE, BENZOISOXAZOLE, AND BENZODIOXOLE ANALOGS AS RXFP1 RECEPTOR AGONISTS BRISTOL MYERS SQUIBB CO (US) 2025-02-27 US disclosed
WO-2023114822-A1 BENZOTHIAZOLE, BENZOISOXAZOLE AND BENZODIOXOLE ANALOGS AS RXFP1 RECEPTOR AGONISTS BRISTOL-MYERS SQUIBB COMPANY (US) 2023-06-22 WO disclosed
WO-2023076626-A1 RXFP1 AGONISTS BRISTOL-MYERS SQUIBB COMPANY (US) 2023-05-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250221966-A1 RXFP1 AGONISTS RXFP1, RXFP2, RXFP3 HSP90AA1 2640/4885HSP90AB1 2817/4885MIF 3202/4885
US-20250066344-A1 BENZOTHIAZOLE, BENZOISOXAZOLE, AND BENZODIOXOLE ANALOGS AS RXFP1 RECEPTOR AGONISTS RXFP1, RXFP2, RXFP3 HSP90AA1 1700/4885HSP90AB1 1765/4885MIF 3976/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.